Synthesis and biological evaluation of copper-64 radiolabeled [DUPA-6-Ahx-(NODAGA)-5-Ava-BBN(7-14)NH2], a novel bivalent targeting vector having affinity for two distinct biomarkers (GRPr/PSMA) of prostate cancer

Nuclear Medicine and Biology

Volumn 41, Issue 4, 2014, Pages 355-363

  Bandari, Rajendra Prasad ^a,b   Jiang, Zongrun ^a,c   Reynolds, Tamila Stott ^a,d   Bernskoetter, Nicole E ^a,b   Szczodroski, Ashley F ^a   Bassuner, Kurt J ^b   Kirkpatrick, Daniel L ^b   Rold, Tammy L ^a,b   Sieckman, Gary L ^a   Hoffman, Timothy J ^a,b,c   Connors, James P ^b   Smith, Charles J ^a,b,c  

^a Research Service   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

Author keywords

Bombesin; Copper 64; Gastrin releasing peptide; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

COPPER 2 [3 (1,3 DICARBOXYPROPYL) UREIDO]PENTANEDIOIC ACID 6 AMINOHEXANOIC ACID 2 (4,7 BISCARBOXYMETHYL) 1,4,7 (TRIAZONAN 1 YL)PENTANEDIOIC ACID 5 AMINOVALERIC ACID BOMBESIN CU 64; GASTRIN RELEASING PEPTIDE RECEPTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; BINDING COMPETITION; CELL STRAIN LNCAP; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROSTATE CANCER; RECEPTOR BINDING; REVERSED PHASE LIQUID CHROMATOGRAPHY; TUMOR XENOGRAFT;

BOMBESIN; COPPER-64; GASTRIN-RELEASING PEPTIDE; PROSTATE CANCER; PROSTATE-SPECIFIC MEMBRANE ANTIGEN;

ACETATES; AMINO ACIDS, NEUTRAL; AMINOCAPROIC ACID; ANIMALS; ANTIGENS, SURFACE; BIOLOGICAL TRANSPORT; BOMBESIN; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; COPPER RADIOISOTOPES; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; GLUTARATES; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE; MICE; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; PROTEIN BINDING; RADIOCHEMISTRY; RECEPTORS, BOMBESIN; TUMOR MARKERS, BIOLOGICAL; UREA;

EID: 84895483997     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.01.001     Document Type: Article

References (47)

1. American Cancer Society Cancer facts & figures 2013.
2. Chen Y., Dhara S., Banerjee S.R., Byun Y., Pullambhatla M., Mease R.C., et al. A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 2009, 390:624-629.
3. Banerjee S.R., Foss C.A., Castanares M., Mease R.C., Byun Y., Fox J.J., et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008, 51:4504-4517.
4. Hillier S.M., Maresca K.P., Femia F.J., Marquis J.C., Foss C.A., Nguyen N., et al. Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res 2009, 69:6932-6940.
5. 2], in a prostate tumor xenografted mouse model. Nucl Med Biol 2010, 37:751-761.
6. Cescato R., Maina T., Nock B., Nikolopoulou A., Charalambidis D., Piccand V., et al. Bombesin receptor antagonists may be preferable to agonists for tumor targeting. J Nucl Med 2008, 49:318-326.
7. Jensen R.T., Battey J.F., Spindel E.R., Benya R.V. International union of pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev 2008, 60:1-42.
8. 177Lu-labeled GRP-R agonist for systemic radiotherapy in human tissues. Clin Exp Metastasis 2009, 26:105-119.
9. Chang S.S., Reuter V.E., Heston W.D.W., Bander N.H., Grauer L.S., Gaudin P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999, 59:3192-3198.
10. Rajasekaran A.K., Anilkumar G., Christiansen J.J. Is prostate-specific membrane antigen a multifunctional protein?. Am J Physiol Cell 2005, 288:C975-C981.
11. Foss C.A., Mease R.C., Fan H., Wang Y., Ravert H.T., Dannals R.F., et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res 2005, 11:4022-4028.
12. Eder M., Schäfer M., Bauder-Wüst U., Hull W.E., Wängler C., Mier W., et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012, 23:688-697.
13. Kularatne S.A., Wang K., Santhapuram H.K.R., Low P.S. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand. Mol Pharm 2009, 6:780-789.
14. 99mTc-radioimaging agents. Mol Pharm 2009, 6:790-800.
15. Anderson C.J., Welch M.J. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 1999, 99:2219-2234.
16. 2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. PNAS 2007, 104:12462-12467.
17. Bass L.A., Wang M., Welch M.J., Anderson C.J. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000, 11:527-532.
18. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004, 45:1390-1397.
19. Rogers B.E., Bigott H.M., McCarthy D.W., Della Manna D., Kim J., Sharp T.L., et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem 2003, 14:756-763.
20. 64Cu-labeled polyethylene glycol-bombesin conjugate. Cancer Biother Radiopharm 2004, 19:25-34.
21. Boswell C.A., Sun X., Niu W., Weisman G.R., Wong E.H., Rheingold A.L., et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem 2004, 47:1465-1474.
22. 3-octreotate using a cross-bridged macrocyclic chelator. Clin Cancer Res 2004, 10:8674-8682.
23. Sun X., Wuest M., Weisman G.R., Wong E.H., Reed D.P., Boswell C.A., et al. Radiolabeling and in vivo behavior of copper-64-labeled cross-bridged cyclam ligands. J Med Chem 2002, 45:469-477.
24. Kukis D.L., Diril H., Greiner D.P., DeNardo S.J., DeNardo G.L., Salako Q.A., et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer 1994, 73:779-786.
25. Kukis D.L., Li M., Meares C.F. Selectivity of antibody-chelate conjugates for binding copper in the presence of competing metals. Inorg Chem 1993, 32:3981-3982.
26. Delgado R., Sun Y., Motekaitis R.J., Martell A.E. Stabilities of divalent and trivalent metal ion complexes of macrocyclic triazatriacetic acids. Inorg Chem 1993, 32:3320-3326.
27. Wieghardt K., Bossek U., Chaudhuri P., Herrmann W., Menke B.C., Weiss J. 1,4,7-Triazacyclononane-N, N', N″-triacetate (TCTA), a hexadentate ligand for divalent and trivalent metal ions. Crystal structures of [CrIII(TCTA)], [FeIII(TCTA)], and Na[CuII(TCTA)]·2NaBr·8H2O. Inorg Chem 1982, 21:4308-4314.
28. 64Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009, 50:1168-1177.
29. 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur J Nucl Med Mol Imaging 2009, 36:1483-1494.
30. Wen X., Chao C., Ives K., Hellmich M.R. Regulation of bombesin-stimulated cyclooxygenase-2 expression in prostate cancer cells. BMC Mol Biol 2011, 12:29.
31. Reile H., Armatis P., Schally A. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 1994, 25:29-38.
32. Kozikowski A.P., Zhang J., Nan F., Petukhov P.A., Grajkowska E., Wroblewski J.T., et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004, 47:1729-1738.
33. 3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors. Nucl Med Biol 2014, 41:133-139.
34. 2]: a site-directed radiopharmaceutical for positron-emission tomography imaging of T-47D human breast cancer tumors. Nucl Med Biol 2009, 36:171-181.
35. Graham K., Lesche R., Gromov A.V., Boehnke N., Schaefer M., Hassfeld J., et al. Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer. J Med Chem 2012, 55:9510-9520.
36. 2: a heterodimeric targeting vector for positron emission tomography imaging of prostate cancer. Nucl Med Biol 2012, 39:377-387.
37. Liu Z., Yan Y., Chin F.T., Wang F., Chen X. Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J Med Chem 2009, 52:425-432.
38. Shi J., Kim Y.S., Zhai S., Liu Z., Chen X., Liu S. Improving tumor uptake and pharmacokinetics of64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem 2009, 20:750-759.
39. Maddalena M.E., Fox J., Chen J., Feng W., Cagnolini A., Linder K.E., et al. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med 2009, 50:2017-2024.
40. 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem 2009, 20:1016-1025.
41. Chen K., Conti P.S. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev 2010, 62:1005-1022.
42. 99mTc: a preclinical study. J Med Chem 2005, 48:100-110.
43. Mansi R., Wang X., Forrer F., Waser B., Cescato R., Graham K., et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011, 38:97-107.
44. Abiraj K., Mansi R., Tamma M.-L., Fani M., Forrer F., Nicolas G., et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med 2011, 52:1970-1978.
45. Abd-Elgaliel W.R., Gallazzi F., Garrison J.C., Rold T.L., Sieckman G.L., Figueroa S.D., et al. Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector. Bioconjug Chem 2008, 19:2040-2048.
46. Nanda P.K., Pandey U., Bottenus B.N., Rold T.L., Sieckman G.L., Szczodroski A.F., et al. Bombesin analogues for gastrin-releasing peptide receptor imaging. Nucl Med Biol 2012, 39:461-471.
47. Nanda P.K., Rold T.L., Sieckman G.L., Szczodroski A.F., Hoffman T.J., Rogers B.E., et al. Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist versus antagonist ligands. In Vivo 2012, 26:583-592.